AbbVie (ABBV) Gets CHMP Nod for Lymphoma Drug's Expanded Use

AbbVie (ABBV) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a positive opinion recommending granting conditional marketing authorization for the expanded use of its drug Tepkinly (epcoritamab) for treating relapsed/refractory follicular lymphoma (R/R FL).AbbVie is seeking approval for Tepkinly in the EU as a monotherapy for the treatment of adult patients with R/R FL after two or more prior therapies. The European Commission’s decis ...